Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Do Not Call” registry

This article was originally published in The Tan Sheet

Executive Summary

House Energy & Commerce Committee unanimously approves HR 395, which would permit FTC to collect fees for implementing a national "do not call" registry to stop unwanted telemarketer calls, Chairman Billy Tauzin (R-La) announces Jan. 29. Measure is expected to reach House floor in early February. Omnibus approps bill authorizes $16 mil. for registry (1"The Tan Sheet" Jan. 13, 2002, p. 16)...

You may also be interested in...



House Commerce Cmte. Backs FTC “Do Not Call” Registry Funding For FY ’03

The House Committee on Energy & Commerce is committed to providing FY 2003 funding for the Federal Trade Commission's "do not call" registry, according to a committee staffer

Can Organovo Leverage Its Solid Phase II Data In MASH?

Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.

Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune

The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel